Bicycle Therapeutics plc (BCYC) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.58
↓-74% vs avg
5yr avg: 2.24
30Y Low0.8·High4.4
ROE
↓
-31.2%
↓+15% vs avg
5yr avg: -36.7%
30Y Low-262%·High-29%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCYC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bicycle Therapeutics plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $357M | $491M | $815M | $644M | $878M | $1.5B | $344M | $104M | — | — | — |
| Enterprise Value | $-253892534 | $-120087747 | $-55120698 | $162M | $583M | $1.1B | $223M | $14M | — | — | — |
| P/E Ratio → | -1.63 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.91 | 6.76 | 23.10 | 23.85 | 60.70 | 130.42 | 33.08 | 7.55 | — | — | — |
| P/B Ratio | 0.58 | 0.80 | 1.03 | 1.73 | 3.24 | 4.41 | 3.60 | 1.12 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCYC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.65 | -1.56 | 6.01 | 40.32 | 96.71 | 21.51 | 1.01 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BCYC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Bicycle Therapeutics plc earns an operating margin of -341.3%. Operating margins have expanded from -704.1% to -341.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -31.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -390.3% | -480.1% | 100.0% | 100.0% | -219.0% | -85.1% | -190.9% | -476.0% | — |
| Operating Margin | -341.3% | -341.3% | -595.0% | -704.1% | -806.6% | -561.0% | -500.1% | -190.6% | -304.7% | -787.0% | — |
| Net Profit Margin | -301.7% | -301.7% | -479.2% | -669.7% | -779.3% | -571.2% | -491.0% | -221.8% | -306.1% | -789.3% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.2% | -31.2% | -29.0% | -56.3% | -36.5% | -30.3% | -54.1% | -261.9% | — | — | -168.4% |
| ROA | -26.2% | -26.2% | -21.8% | -35.9% | -25.3% | -20.9% | -37.6% | -31.9% | -28.1% | -37.9% | -114.2% |
| ROIC | — | — | — | — | — | — | — | -663.7% | — | — | — |
| ROCE | -32.0% | -32.0% | -29.7% | -43.0% | -29.1% | -22.6% | -43.4% | -30.2% | -31.7% | -44.7% | -168.2% |
BCYC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $628M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.01 | 0.12 | 0.16 | 0.13 | 0.17 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | -1.10 | -1.30 | -1.09 | -1.14 | -1.26 | -0.97 | — | — | -1.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1061.17 | -1061.17 | -99.46 | -58.21 | -33.16 | -21.95 | -113.70 | — | — | — | — |
Net cash position: cash ($628M) exceeds total debt ($18M)
BCYC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Bicycle Therapeutics plc's current ratio of 11.02x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 8.08x to 11.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.02 | 11.02 | 13.81 | 8.08 | 6.92 | 12.65 | 6.73 | 11.81 | 8.60 | 7.57 | 2.96 |
| Quick Ratio | 11.02 | 11.02 | 13.81 | 8.08 | 6.92 | 12.65 | 6.73 | 11.81 | 8.60 | 7.57 | 2.96 |
| Cash Ratio | 11.02 | 11.02 | 13.08 | 7.57 | 6.36 | 12.11 | 5.88 | 10.44 | 7.10 | 7.16 | 2.47 |
| Asset Turnover | — | 0.10 | 0.04 | 0.05 | 0.04 | 0.02 | 0.06 | 0.13 | 0.09 | 0.03 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 178.99 | 368.91 | 325.26 | 535.20 | 371.65 | 514.06 | 188.97 | 578.65 | 531.73 | — |
BCYC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bicycle Therapeutics plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $69M | $58M | $36M | $30M | $25M | $19M | $11M | $13M | $13M | $18M |
Peer Comparison
Compare BCYC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCYCYou | $357M | -1.6 | — | — | 100.0% | -341.3% | -31.2% | — | — |
 PEPG | $127M | -0.9 | — | — | — | — | -67.4% | -73.2% | — |
 CYCN | $14M | -3.0 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 TERN | $5B | -47.3 | — | — | — | — | -29.6% | -42.2% | — |
 AGIO | $2B | -3.8 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TGTX | $7B | 15.2 | 55.7 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 NUVL | $7B | -26.5 | — | — | — | — | -29.5% | -32.6% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See BCYC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCYC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCYC vs PEPG
Side-by-side business, growth, and profitability comparison vs PepGen Inc..
Start ComparisonBCYC — Frequently Asked Questions
Quick answers to the most common questions about buying BCYC stock.
What is Bicycle Therapeutics plc's P/E ratio?
Bicycle Therapeutics plc's current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
What is Bicycle Therapeutics plc's ROE?
Bicycle Therapeutics plc's return on equity (ROE) is -31.2%. The historical average is -83.5%.
Is BCYC stock overvalued?
Based on historical data, Bicycle Therapeutics plc is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Bicycle Therapeutics plc's profit margins?
Bicycle Therapeutics plc has 100.0% gross margin and -341.3% operating margin.